Sitemap
- March 2007 Monthly Safety Labeling Changes
- October 2006 Monthly Safety Labeling
- September 2006 Safety Labeling Changes
- July 2006 Safety Related Labeling changes
- Friday's Health Winners & Losers
- Novartis Consumer Health (NVS) Receives Approval for Thrive - Nicotine ...
- FDA Issues Approvable Letter For RISPERDAL(R) To Treat Adolescents ...
- Need to know
- J&J's Risperdal approvable for children
- Schizophrenia and Bipolar Mania Treatment in Adolescents and Children ...
- FDA conditionally approves Risperdal for children
- FDA Wants More Information on Risperdal
- Release for J&J antipsychotic drug to treat teens delayed
- FDA Issues Approvable Letter for Risperdal to Treat Adolescents with ...
- LAB International Licenses Fentanyl Taifun to Janssen Pharmaceutica NV ...
- Corcept Therapeutics Announces Positive Results From Its Proof of
- Medical marijuana bill passes in Assembly
- Alkermes to Webcast Analyst and Investor Day
- Kathy Sheran: Shine more light on drug clinical trials
- More Air for Alkermes
- Johnson & Johnson's Pretty Pipeline
- Risperdal - Drug Description
- Antipsychotic Drugs Raise Death Rates in Elderly
- Bear Stearns Boston Biotech Confab to Webcast Alkermes' Corporate ...
- Bad Alkermes?
- Alkermes Slips Amid SEC Probe
- Alkermes down on Vivitrol concerns
- Alkermes Reports Unaudited Financial Results for Fiscal 2007 and ...
- Autism Organizations
- Antipsychotic Iloperidone Results Show Favorable Akathisia Profile
- Diabetes drug use spikes in young girls
- Antipsychotics in Kids: The New York Times Gets it Completely Wrong
- to Our Sponsors
- Risperdal Approved for Autism Symptoms in Children
- Where money, medicine intersect - debate
- Daily Health Policy Report
- Shrinks Who Get Payments Prescribe Most Often To Kids
- Psychiatrists, Children and Drug Industry’s Role
- When Money and Medicine Intersect
- Pricking For Success
- FDA Approves INVEGA For Long-Term Maintenance Treatment Of ...
- War veterans find a haven in local hospital
- J&J schizophrenia drug gets nod for wider use
- Medications For Mental Health
- College counseling centers overwhelmed
- Bennings to be tried in wife’s slaying
- Gemin X compound effective in leukemia
- J&J 1Q profit falls 22 percent
- J&J schizophrenia drug OK'd by FDA
- FDA Approves New Dose of Risperdal Consta for Schizophrenia Treatment
- Mylan Labs Sees Higher Profit
- CIBC World Markets Annual Biotechnology & Specialty
- Autism Organizations
- Autism Organizations
- Dementia patients dying early on sedatives: study
- Autism Organizations
- Alzheimer's Disease
- J&J gets subpoenas over three drugs
- Why I won't give up on Lewis
- BUSINESS NEWS
- Autism Organizations
- Today's Top Stories
- J&J receives three subpoenas
- Boston prosecutors subpoena Drug Company Records
- J&J Gets Subpoenas Over Three Drugs
- J&J gets subpoenas over three drugs
- Business Briefs - Monday
- J&J hit by subpoenas over sales practices
- Johnson & Johnson Gets Subpoenas Related to 3 Drugs
- Activists take on Eli Lilly over off-label sale of Zyprexa
- Alkermes Names New CEO
- Studies Compare New Antipsychotic Drugs
- Psychiatric Drugs: The New Pharmacopoeia
- FDA Grants Pediatric Exclusivity For RISPERDAL(R)
- Studies Compare New Antipsychotic Drugs
- UPI NewsTrack Health and Science News
- Pediatric exclusivity granted on Risperdal
- Studies focus on schizophrenia treatment
- Eli Lilly's Zyprexa Will Remain The Clinical Gold Standard For The ...
- In schizophrenia, drugs may be personal matter
- Eli Lilly's Zyprexa Will Remain the Clinical Gold Standard for the ...
- Job, family counseling key to schizophrenics' independence
- Girl's death puts doctor at center of controversy
- Preliminary Program: Wednesday, May 23
- Debate Over Children and Psychiatric Drugs
- Akamai revenue rises 52 percent
- Alkermes 3Q profit doubles
- Alkermes Raises 2007 Forecasts
- Weitz & Luxenberg Responds to Study on Off-Label Use of Antipsychotics
- Cure for Colic?
- Antipsychotic drug controls some symptoms in autism disorder
- Diabetes Drug Halts Weight Gain in Kids Taking Antipsychotics
- Page 3 of 3
- Quarterly revenue generated by the world's largest health-care company ...
- Drug fear hinders treatment of mentally ill
- Study Questions 'Off-Label' Use of Antipsychotics
- Accused refuses to attend his trial
- Evidence Lacking to Support Many Off-Label Uses of Atypical ...
- Drug fear hinders treatment of mentally ill
- Diabetes Drug Halts Weight Gain in Kids Taking Antipsychotics
- State report: Millions saved thwarting Medicaid fraud
- Paths to self-discovery differ for two students
- On the blog now:
- Tally of novel drug approvals stays at same level
- More Risperdal MSN Newsfeeds...
- Focus -- Sign In Page
- Highlights of this issue -- Dean 192 (6): A22 -- The British Journal of Psychiatry
- BJP -- Sign In Page
- J&J Presents Encouraging Data From Risperidone Injection Trail - Health - redOrbit
- BJP -- Sign In Page
- BJP -- Sign In Page
- WXVT-TV Delta News - More Local News and Weather WXVT.com | Arkansas AG sues AstraZeneca over anti-psychotic drug
- CNW Group | INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES | 'Antipsychotic drugs prescribed in the elderly may be dangerous'
- Antipsychotics In Older Adults With Dementia Associated With Serious Adverse Events And Death
- Antipsychotic drugs raise death risk in dementia patients
- Dementia patients get antipsychotic side effects - www.6minutes.com.au
- Study: Elderly People With Dementia Taking Antipsychotic Drugs Are Much More Likely To Die Or Get Hospitalized | TopNews US Edition
- Antipsychotic drug warning (27.05.08) | Age Concern England
- Short-term Antipsychotic Therapy Leads to Increased Heath Risks - Health - redOrbit
- Antipsychotic drugs dangerous for the elderly
- Antipsychotic Drugs Appear to be Potential Killers for Senior Citizens with Dementia
- Report: Danger tripled for seniors with dementia taking antipsychotics - McKnight's Long Term Care News
- Business Feed Article | Business |
- Bloomberg.com: Canada
- Antipsychotics Dangerous for Elderly With Dementia - washingtonpost.com
- CTV.ca | Antipsychotic drugs raise risks for dementia patients
- Use of anti-psychotic drugs linked to spike in deaths of dementia patients, study finds
- Loose Threads: No End in Sight » North by Northwestern
- Alkermes rises as analyst names it a 'Top Pick' - Forbes.com
- Daily Herald | Suspect in 'Angel of Death' case asks court to dismiss charges
- Former nursing home employee asks judge to throw out charges linked to suspicious deaths -- Medical Staff, Crossroads -- chicagotribune.com
- Defendant wants charges thrown out -- Prosecution -- chicagotribune.com
- Therapeutics Daily
- Bayer and J&J anticoagulant reduces blood clots 31 pct more than Sanofi-Aventis' drug: study - International Business Times -
- Bayer: Study shows Rivaroxaban superiority to Lovenox - MarketWatch
- Bayer:Study Shows Rivaroxaban Superiority Vs Standard Therapy
- J&J blood clot drug beats Sanofi-Aventis' Lovenox
- Bayer, J&J clot-drug success lifts U.S. prospects | Markets | Hot Stocks | Reuters
- Analyst: J&J blood-clot drug poised for success
- Covering the Hudson to the Catskills!
- News: Schizophrenia and Bipolar Mania Treatment in Adolescents and Children Added to Risperdal’s Label. Genetic Engineering News - Biotechnology from Bench to Business
- NJBIZ.com
- FDA conditionally approves Risperdal for children| Health| Reuters
- FDA Wants More Information on Risperdal - Forbes.com
- SignOnSanDiego.com > News > Business -- FDA conditionally approves Risperdal for children
- Johnson & Johnson asked by FDA for more information on Risperdal | Latest News | News | Hemscott
- FDA wants more information on Risperdal | Latest News | News | Hemscott
- APP.COM - Regulators hold off on approving Johnson & Johnson drug for teens | Asbury Park Press Online
- Johnson & Johnson Pharmaceutical Research and Development, L.L.C. :: FDA Issues Approvable Letter for RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
- PRdomain.com | Johnson & Johnson | FDA approves two supplemental drug applications by Johnson and Johnson
- FDA Issues Approvable Letter for RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania - PipelineReview.com | Business Intelligence Center
- Schizophrenia Treatment > FDA Approves RISPERDAL To Treat Adolescents with Schizophrenia
- J&J to Answer FDA Request - News & Analysis - Pharmaceuticals - JNJ - JNJ
- FDA Wants More Information on Risperdal | Chron.com - Houston Chronicle
- Shire says gets U.S. approval signal on ADHD drug| Health| Reuters
- UPDATE 1-Shire gets U.S. approval signal on new ADHD drug| Health| Reuters
- The Hindu News Update Service
- Shire Says FDA May OK ADHD Drug - Forbes.com
- State Moves Against Troubled LA Hospital - Newsday.com
- Shire gets approvable letter for nonstimulant ADHD drug - Philadelphia Business Journal:
- StreetInsider.com - Opexa Therapeutics (OPXA) Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
- Briefing.com Business News: Market Report -- In Play (OPXA) - MSN Money
- RTTNews - Breaking News, financial breaking News, Positive EPS Surprises, Stock research ....
- United Press International - Health Business - Briefing
- Opexa Cites Positive Tovaxin Results | Chron.com - Houston Chronicle
- PharmaLive: Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
- News: Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin(TM) for Multiple Sclerosis. Genetic Engineering News - Biotechnology from Bench to Business
- Daytrading, Eminis, Forex trading, Swing Trading BREAKING NEWS - 566624
- Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin(TM) for Multiple Sclerosis - PipelineReview.com | Business Intelligence Center
- Opexa Cites Positive Tovaxin Results - Forbes.com
- Novartis: Exforge Gets Final US Approval -2- | Nachrichten |
- RTTNews - Breaking News, financial breaking News, Positive EPS Surprises, Stock research ....
- Therapeutics Daily
- Novartis' Exforge Receives FDA Approval
- Novartis gets FDA approval for blood pressure drug | newratings.com
- United Press International - Health Business - Briefing
- Novartis receives FDA approval for blood pressure medicine - Pharmaceutical Business Review
- FDA gives go-ahead to once-daily valsartan-amlodipine combo pill for HTN
- Novartis gets final U.S. approval for Exforge| News| Regulatory News| Reuters
- Novartis says it won approval for blood pressure treatment Exforge - International Herald Tribune
- FDA approves blood pressure combo from Novartis, Pfizer - Jun. 21, 2007
- Novartis broad pipeline will help it over setbacks| Reuters
- Exforge(R) Receives Final US Approval as New and Powerful Treatment Option for Patients With High Blood Pressure
- News: Exforge(R) Receives Final US Approval as New and Powerful TreatmentOption for Patients With High Blood Pressure. Genetic Engineering News - Biotechnology from Bench to Business
- Exforge(R) Receives Final US Approval as New and Powerful Treatment Option for Patients With High Blood Pressure
- Novartis' blood pressure drug Exforge receives final clearance by FDA
- Euro2day :: Novartis' blood pressure drug Exforge receives final clearance by FDA
- Daytrading, Eminis, Forex trading, Swing Trading BREAKING NEWS - 566212
- RTTNews - Breaking News, financial breaking News, Positive EPS Surprises, Stock research ....
- News: Exforge(R) Receives Final US Approval as New and Powerful TreatmentOption for Patients With High Blood Pressure. Genetic Engineering News - Biotechnology from Bench to Business
- Novartis' combo hypertension drug approved in US
- Novartis to Sell Exforge in U.S. - News & Analysis - Pharmaceuticals - NVS - PFE
- Novartis Pharmaceuticals Corporation :: Exforge(R) Receives Final US Approval as New and Powerful Treatment Option for Patients With High Blood Pressure
- Exforge(R) receives final US approval as new and powerful treatment option for patients with high blood pressure - PipelineReview.com | Business Intelligence Center
- UPDATE 1-Novartis gets final U.S. approval for Exforge| Health| Reuters
- Novartis Wins Approval for Exforge | Chron.com - Houston Chronicle
- Novartis Wins Approval for Exforge - Forbes.com
- Briefing.com Business News: Market Report -- In Play (AKRX) - MSN Money
- United Press International - Health Business - Briefing
- Akorn teams up with India's Cipla for drug development| News| Regulatory News| Reuters
- Akorn teams up with Cipla for drug development | Reuters.com
- StreetInsider.com - Akorn (AKRX) and Cipla Sign Drug Development and Supply Agreement
- PharmaLive: Akorn, Inc. and Cipla, Ltd. Announce the Signing of an Exclusive Drug Development and Supply Agreement for an Oral ANDA Drug Product for the Prevention of Organ Transplant Rejection
- Novo Nordisk drug candidate Liraglutide successful in phase 3 trial | Latest News | News | Hemscott
- Novo Nordisk drug data a 'positive surprise' - BloggingStocks
- More Risperdal News Articles...
- Risperidone may prevent falls in dementia patients. (Decreased Wandering). : An article from: Clinical Psychiatry News
- Risperidone augmentation of clozapine works! risperidone augmentation of clozapine doesn't work!: a tale of two protocols.(Second Messenger): An article ... Educational Updates (PsychEd Up)
- Selected drugs used in pediatric patients: pharmacology update.: An article from: Pediatric Nursing
- Atypical Antipsychotic Drugs: Part 1.(Statistical Data Included): An article from: Perspectives in Psychiatric Care
- First-line atypicals have similar efficacy in schizophrenia.(Adult Psychiatry): An article from: Clinical Psychiatry News
- Effects of fluoxetine, risperidone and alprazolam on pharmacokinetics of lithium in patients with psychiatric illness.: An article from: Indian Journal of Pharmacology
- Switching rx may reduce hyperprolactinemia.(Adult Psychiatry): An article from: Clinical Psychiatry News
- IM formulations widen atypical antipsychotic uses: intramuscular ziprasidone, others.(Psychopharmacology): An article from: Clinical Psychiatry News
- Atypical antipsychotics offer modest therapeutic advantage. (Beyond Superior Side Effect Profile).(Brief Article): An article from: Clinical Psychiatry News
- Careful monitoring of children on atypicals is critical. (Fasting Glucose, Lipids Every 3 Months).: An article from: Clinical Psychiatry News
- Olanzapine vs. risperidone in schizophrenia.(leading antipsychotic drugs comparison): An article from: Clinical Psychiatry News
- Risperidone soothes teens' externalizing behavior: compared with olanzapine.(Child/Adolescent Psychiatry): An article from: Clinical Psychiatry News
- Study compares efficacy of two schizophrenia drugs: risperidone.(Children's Health): An article from: Family Practice News
- The newest atypical antipsychotic--paliperidone.(RX Primer)(Drug overview): An article from: Annals of the American Psychotherapy Association
- Risperidone augmentation of clozapine works! Risperidone augmentation of clozapine doesn't work! A tale of two protocols.(Second Messenger): An article from: Clinical Psychiatry News
- Long-term risperidone benefits autistic children. (Reduces Disruptive Behavior).: An article from: Pediatric News
- Long-term risperidone reduces disruptiveness in autistic children. (Well Tolerated).: An article from: Clinical Psychiatry News
- Intervention may delay psychosis in schizophrenia: patients who received risperidone and therapy had 29% absolute risk reduction. (More Trials Underway).: An article from: Clinical Psychiatry News
- Risperidone may prevent falls in dementia patients. (Decreased Wandering).: An article from: Clinical Psychiatry News
- Risperidone use linked to pituitary tumors.(drug therapy): An article from: Clinical Psychiatry News
- Long-acting, injectable risperidone on horizon. (Approval Expected This Year).: An article from: Clinical Psychiatry News
- Risperidone quells disruptive behavior in ADHD patients. (Adjunctive Therapy).(Brief Article): An article from: Clinical Psychiatry News
- Two drugs most effective in psychotic substance abusers. (Ziprasidone, Risperidone).(Brief Article): An article from: Clinical Psychiatry News
- Short-Term risperidone cuts Tourette's tics. (More Study Needed).(Brief Article)(Statistical Data Included): An article from: Clinical Psychiatry News
- Low-Dose Risperidone Is Effective, Well Tolerated in Dementia Patients.(Brief Article)(Statistical Data Included): An article from: Family Practice News
- Risperdal: Risperidone, clinical monograph
- Risperidone use in the treatment of behavioral symptoms in children with autism.: An article from: Pediatric Nursing
- Risperidone may relieve bipolar mania symptoms. (Quick Acting).(Brief Article): An article from: Clinical Psychiatry News
- New findings in the use of atypical antipsychotic drugs: I. Focus on risperidone (The journal of clinical psychiatry case and comment series)
- For girls on risperidone, don't measure prolactin.(Child/Adolescent Psychiatry): An article from: Clinical Psychiatry News
- Risperidone reduced psychotic symptoms in dementia study.(Geriatrics): An article from: Internal Medicine News
- FDA approves first agent for treating autism symptoms: risperidone approval called 'breakthrough.'.(Food and Drug Administration): An article from: Clinical Psychiatry News
- Risperidone is approved for Tx of mania in bipolar disorder.(News): An article from: Clinical Psychiatry News
- Despite arrhythmias, weight gain, newer antipsycotics more effective. (Baseline ECG Recommended).(Brief Article): An article from: Clinical Psychiatry News
- The use of risperidone among individuals with mental retardation: clinically supported or not? [An article from: Research in Developmental Disabilities]
- Risperidone and acute mania.(EVIDENCE-BASED PSYCHIATRIC MEDICINE)(Medical condition overview): An article from: Clinical Psychiatry News
- Indications for risperidone expanded to teens, kids.(NEWS FROM THE FDA): An article from: Clinical Psychiatry News
- Risperidone: An entry from Thomson Gale's Gale Encyclopedia of Mental Disorders
- Risperidone reduces autistic behavioral problems. (May Set Stage for TX of Core Symptoms).: An article from: Clinical Psychiatry News
- Risperidone reduces autistic behavioral problems. (Reduced Tantrums, Aggression).(Brief Article): An article from: Pediatric News
- Risperdal indication extends to teens, kids.(NEWS FROM THE FDA): An article from: Family Practice News
- Long-Acting Risperdal Improves Schizophrenia Symptoms.: An article from: Clinical Psychiatry News
- Primer for prescription medications: the first long-acting atypical antipsychotic.(RX Primer): An article from: Annals of the American Psychotherapy Association
- Risperdal - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References
- Zingo, Risperdal.(New & Approved): An article from: Pediatric News






